• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Editorial Staff
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Zagazig University Medical Journal
Articles in Press
Current Issue
Journal Archive
Volume Volume 25 (2019)
Issue Issue 1
Volume Volume 24 (2018)
Volume Volume 23 (2017)
Volume Volume 22 (2016)
Volume Volume 21 (2015)
Volume Volume 20 (2014)
Volume Volume 19 (2013)
Al-Naggar, M., EL Hariri, M., Hashem, A. (2019). EVALUATION OF ORAL PREGABALIN IN TREATMENT OF PREMATURE EJACULATION. Zagazig University Medical Journal, 25(1), 126-131. doi: 10.21608/zumj.2019.24881
Mohamed Refaat Al-Naggar; Mohamed Dardiri EL Hariri; Abdulrahman Hefny Hashem. "EVALUATION OF ORAL PREGABALIN IN TREATMENT OF PREMATURE EJACULATION". Zagazig University Medical Journal, 25, 1, 2019, 126-131. doi: 10.21608/zumj.2019.24881
Al-Naggar, M., EL Hariri, M., Hashem, A. (2019). 'EVALUATION OF ORAL PREGABALIN IN TREATMENT OF PREMATURE EJACULATION', Zagazig University Medical Journal, 25(1), pp. 126-131. doi: 10.21608/zumj.2019.24881
Al-Naggar, M., EL Hariri, M., Hashem, A. EVALUATION OF ORAL PREGABALIN IN TREATMENT OF PREMATURE EJACULATION. Zagazig University Medical Journal, 2019; 25(1): 126-131. doi: 10.21608/zumj.2019.24881

EVALUATION OF ORAL PREGABALIN IN TREATMENT OF PREMATURE EJACULATION

Article 17, Volume 25, Issue 1, January 2019, Page 126-131  XML PDF (688.96 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.24881
Authors
Mohamed Refaat Al-Naggar; Mohamed Dardiri EL Hariri; Abdulrahman Hefny Hashem
Abstract
Background: Premature ejaculation (PE) is the most common form of male sexual dysfunction. Treatment modalities include behavioral therapy and medical therapy. No therapy is approved by the FDA for treatment of PE. Pregabalin exerts a negative effect on sexuality by reducing central nervous excitatory transmission via sodium and calcium channel inhibition and potassium (k) channel activation and by unbalancing dopamine serotonine ratio. The aim of this work was to assess the efficacy and safety of oral on demand pregabalin in treatment of premature ejaculation (PE).Methods: This study was conducted on 96 married male patients with primary premature ejaculation (lifelong). All patients were recruited from the andrology outpatient clinic at Al-Azhar University Hospitals (Cairo).The patients were randomly assigned to three groups: Group A: This group included 36 patients. They will receive 150 mg pregabalin 1 – 2 hours prior to sexual intercourse. Group B: This group included 30 patients. They will receive 75 mg pregabalin 1 – 2 hours prior to sexual intercourse. Group C: This group included 30 patients, all of them received identical placebo capsules. All patient will be subjected to the following:Full history: including age, baseline estimated ILET, erectile dysfunction, medical diseases and medications. Local and general physical examination. Couples were encouraged to engage in coitus twice a week and record estimated intravaginal ejaculation latency time (perceived IELT OR PIELT) every time for 2 weeks and report any side effects suspected to be drug related. Results: There was no statistically significant difference between group A, B and C regarding base PIELT. PIELT significantly increased after treatment in group A receiving 150 mg pregabalin. Patients in group B showed mild improvement in their PIELT after receiving 75 mg pregabalin. This improvement was statistically significant. There was no statistically significant difference between Base PIELT and PIELT after treatment among group C patients. There was statistically significant difference between group A and C regarding after treatment PIELT. There was no statistically significant difference between group B and C regarding PIELT after treatment. Comparing post treatment ejaculatory time in different groups, PIELT significantly improved in group A rather than placebo group. This was not present in group B. There was significant improvement in PIELT of group A rather than group B. Conclusion: This is the first report of an oral pregabalin used for the treatment of PE in men. On demand oral pregabalin 150 mg 1 – 2 hours prior to sexual relation, looks to be effective pharmacotherapy of PE. The effect of pregabalin is minimal and may be augmented with higher daily doses. Longer-term safety studies, and those comparing pregabalin with on demand tramadol and dapoxetine are essential to determine the place of pregabalin in the treatment of this distressing condition.
Keywords
Premature Ejaculation; Pregabalin; evaluation
Statistics
Article View: 49
PDF Download: 42
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.